sitravatinib
Showing 26 - 27 of 27
NSCLC (NSCLC) Trial in Worldwide (Tislelizumab, Docetaxel, Sitravatinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Tislelizumab
- +2 more
-
Tucson, Arizona
- +112 more
Nov 9, 2022
NSCLC, Carcinoma, Squamous Cell, Adenocarcinoma Trial in United Kingdom (AZD4547, Vistusertib, Palbociclib)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +2 more
- AZD4547
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Nov 2, 2021